- FDA “Breakthrough Device Designation”
- Tox Study Completion
- WMIC 2019 Poster
- Q&A with Bob Proulx
Quarterly Activity Report – Quarter ending 31 December 2023
Highlights: Announced positive results from IBI10103 Phase I Study demonstrating safety and clinical feasibility of molecular MRI with MagSense® HER2 Imaging Agent Presented new animal